VANCOUVER, British Columbia, Jan. 18, 2007 (PRIME NEWSWIRE) -- If you missed MN1's interview with Dr. Kevin Mullane, President and CEO of Inflazyme Pharmaceuticals Ltd. (Other OTC:IZYPF) (TSX:IZP), which aired live on Jan. 11, 2007, you can still catch it by downloading the podcast on www.mn1.com.
During the interview, Dr. Mullane provided an overview of the company, its corporate goals and its position in the stock market.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies to improve the lives of people with respiratory and inflammatory diseases.
Inflazyme has developed capabilities in medicinal chemistry, biochemistry, pharmacology, regulatory and clinical development, and business and finance to build a company that is developing a strong franchise in inflammatory diseases, in particular, respiratory diseases such as asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD).
Again, to access the podcast in its entirety, go to www.MN1.com and download the IZYPF podcast.
About MN1.com
Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.
Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.
The Market News First logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3162